The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

BackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease without standardized treatment strategies. The efficacy of second-line or beyond immune checkpoint inhibitors (ICIs) has been proven in recent studies, whereas the evidence for first-line immunotherapy for PSC is still...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Zhimin Zeng, Xiaoying Qian, Fanrong Liu, Yong Wang, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu, Tong Wang, Yan Yin, Yong Li, Anwen Liu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2022-10-01
Цуврал:	Frontiers in Immunology
Нөхцлүүд:	pulmonary sarcomatoid carcinoma immune checkpoint inhibitors immunotherapy anlotinib camrelizumab tislelizumab
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.956982/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!